Treating anemia in subjects by administration of plasmids...

Details Treating anemia in subjects by administration of plasmids... Treating anemia in subjects by administration of plasmids...

2007-07-10

2007-07-10

Woitach, Joseph (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S063000, C530S399000, C424S093100

Reexamination Certificate

active

10315907

ABSTRACT:
The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and method are useful for retarding the growth of the tumor, and retarding cachexia, wasting, anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded. gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the tissue specific constitutive expression is achieved.

REFERENCES:
patent: 4223019 (1980-09-01), Momany
patent: 4223020 (1980-09-01), Momany
patent: 4223021 (1980-09-01), Momany
patent: 4224316 (1980-09-01), Momany
patent: 4226857 (1980-10-01), Momany
patent: 4228156 (1980-10-01), Momany
patent: 4228158 (1980-10-01), Momany
patent: 4410512 (1983-10-01), Bowers
patent: 4684611 (1987-08-01), Schilperoort
patent: 4833166 (1989-05-01), Grosvenor
patent: 4839344 (1989-06-01), Bowers
patent: 4952500 (1990-08-01), Finnerty
patent: 4956288 (1990-09-01), Barsoum
patent: 5023322 (1991-06-01), Kovacs
patent: 5036045 (1991-07-01), Thorner
patent: RE33699 (1991-09-01), Drengler
patent: 5061690 (1991-10-01), Kann
patent: 5084442 (1992-01-01), Felix
patent: 5134120 (1992-07-01), Boyd
patent: 5137872 (1992-08-01), Seely
patent: 5292721 (1994-03-01), Boyd
patent: 5302523 (1994-04-01), Coffee
patent: 5322783 (1994-06-01), Tomes
patent: 5384253 (1995-01-01), Krzyzek
patent: 5439440 (1995-08-01), Hofmann
patent: 5464765 (1995-11-01), Coffee
patent: 5486505 (1996-01-01), Bowers
patent: 5538877 (1996-07-01), Lundquist
patent: 5538880 (1996-07-01), Lundquist
patent: 5550318 (1996-08-01), Adams
patent: 5563055 (1996-10-01), Townsend
patent: 5580859 (1996-12-01), Felgner
patent: 5589466 (1996-12-01), Felgner
patent: 5591616 (1997-01-01), Hiei
patent: 5610042 (1997-03-01), Chang
patent: 5656610 (1997-08-01), Shuler
patent: 5696089 (1997-12-01), Felix
patent: 5702384 (1997-12-01), Umeyama
patent: 5702932 (1997-12-01), Hoy
patent: 5704908 (1998-01-01), Hofmann
patent: 5736524 (1998-04-01), Content
patent: 5756264 (1998-05-01), Schwartz
patent: 5776901 (1998-07-01), Bowers
patent: 5780448 (1998-07-01), Davis
patent: 5789215 (1998-08-01), Berns
patent: 5792747 (1998-08-01), Schally
patent: 5846936 (1998-12-01), Felix
patent: 5847066 (1998-12-01), Coy
patent: 5874534 (1999-02-01), Vegeto
patent: 5925564 (1999-07-01), Schwartz et al.
patent: 5935934 (1999-08-01), Vegeto
patent: 5945100 (1999-08-01), Fick
patent: 5981274 (1999-11-01), Tyrrell
patent: 5994624 (1999-11-01), Trolinder
patent: 6194402 (2001-02-01), Bach et al.
patent: 6468986 (2002-10-01), Zuckermann et al.
patent: 6551996 (2003-04-01), Schwartz et al.
patent: 1052286 (2000-11-01), None
patent: WO 94/09699 (1994-05-01), None
patent: WO- 95/06128 (1995-03-01), None
patent: WO 99/05300 (1999-02-01), None
patent: WO 99/05300 (1999-02-01), None
patent: WO 01/06988 (2001-02-01), None
Romano et al. “Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications.” 18:19-39, 2000.
Verma et al. “Gene therapy—promises, problems and prospect.” Nature 389:239-242, 1997.
Prchal et al. “Deliver on demand—a new era of gene therapy?” The New England Journal of Medicine 348(13): 1282-1283, 2004.
Bowie, et al. (1990) Science, 247: 1306-10.
Parsons (1976) Peptide Hormones, University Park Press, Baltimore, MD., pp. 1-6.
Gorecki (2001) Exp. Opin. Emerg. Drugs, 6(2): 187-98.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1):53-69.
Rivera, et al. (2005) Blood, 105(1):382-86.
Ballas, et al. (2004) Microcirculation, 11: 209-25.
Abruzzese,R.V., Godin,D., Burcin,M., Mehta,V., French,M., Li,Y., O'Malley,B.W., and Nordstrom,J.L. (1999). Ligand-dependent regulation of plasmid-based transgene expression in vivo. Hum. Gene Ther. 10, 1499-1507.
Aihara,H. and Miyazaki,J. (1998). Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16, 867-870.
Al Suwaidi,J., Reddan,D.N., Williams,K., Pieper,K.S., Harrington,R.A., Califf,R.M., Granger,C.B., Ohman,E.M., and Holmes,D.R., Jr. (2002). Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106, 974-980.
Almendro,N., Bellon,T., Rius,C., Lastres,P., Langa,C., Corbi,A., and Bernabeu,C. (1996). Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization. J. Immunol. 157, 5411-5421.
Aratani,Y., Okazaki,R., and Koyama,H. (1992). End extension repair of introduced targeting vectors mediated by homologous recombination in mammalian cells. Nucleic Acids Res. 20, 4795-4801.
Argente,J., Pozo,J., and Chowen,J.A. (1996). The growth hormone axis: control and effects. Hormone Research 45 Suppl 1, 9-11.
Barber,M.D., Ross,J.A., and Fearon,K.C. (1999). Cancer cachexia.Surg. Oncol. 8, 133-141.
Bartlett,D.L., Charland,S., and Torosian,M.H. (1994). Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer 73, 1499-1504.
Bercu,B.B., Walker,R.F.(1997). Growth Hormone Secretagogues in Children with Altered Growth. Acta Paediatrica 86, 102-106.
Bettan,M., Emmanuel,F., Darteil,R., Caillaud,J.M., Soubrier,F., Delaere,P., Branelec,D., Mahfoudi,A., Duverger,N., and Scherman,D. (2000). High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol. Ther. 2, 204-210.
Blethen,S.L. and MacGillivray,M.H. (1997). A risk-benefit assessment of growth hormone use in children. Drug Saf 17, 303-316.
Blethen,S.L. and Rundle,A.C. (1996). Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Horm. Res. 46, 113-116.
Bohlen,P., Esch,F., Brazeau,P., Ling,N., and Guillemin,R. (1983). Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. Biochem. Biophys. Res. Commun. 116, 726-734.
Boshart,M., Weber,F., Jahn,G., Dorsch-Hasler,K., Fleckenstein,B., and Schaffner,W. (1985). A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41, 521-530.
Bureau,M.F., Gehl,J., Deleuze,V., Mir,L.M., and Scherman,D. (2000). Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim. Biophys. Acta 1474, 353-359.
Carbonelli,D.L., Corley,E., Seigelchifer,M., and Zorzopulos,J. (1999). A plasmid vector for isolation of strong promoters inEscherichia coli. FEMS Microbiol. Lett. 177, 75-82.
Chandler,S.D., Mayeda,A., Yeakley,J.M., Krainer,A.R., and Fu,X.D. (1997). RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins. Proc. Natl. Acad. Sci. U. S. A 94, 3596-3601.
Chen,C. and Okayama,H. (1987). High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol. 7, 2745-2752.
Chevalier,R.L., Goyal,S., Kim,A., Chang,A.Y., Landau,D., and Leroith,D. (2000). Renal tubulointerstitial injury from ureteral obstruction in the neonatal rat is attenuated by IGF-1. Kidney Int. 57, 882-890.
Claustres,M., Chatelain,P., and Sultan,C. (1987). Insulin-like growth factor I stimulates human erythroid colony formation in vitro. J Clin. Endocrinol. Metab 65, 78-82.
Cocea,L. (1997). Duplication of a region in the multiple cloning site of a plasmid vector to enhance cloning-mediated addition of restriction sites to a DNA fragment. Biotechniques 23, 814-816.
Corpas,E., Harman,S.M., Pineyro,M.A., Roberson,R., and Blackman,M.R. (1993). Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men. Journal of Clli

Affiliated with

Also associated with

Rating

Treating anemia in subjects by administration of plasmids... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treating anemia in subjects by administration of plasmids..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating anemia in subjects by administration of plasmids... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3730397